Knight Therapeutics (TSE:GUD) Shares Down 0.2% – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) dropped 0.2% during trading on Monday . The stock traded as low as C$5.65 and last traded at C$5.70. Approximately 36,840 shares were traded during trading, a decline of 37% from the average daily volume of 58,048 shares. The stock had previously closed at C$5.71.

Wall Street Analysts Forecast Growth

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th.

Knight Therapeutics Trading Down 0.2 %

The firm has a market cap of C$576.90 million, a PE ratio of -28.50, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a 50-day simple moving average of C$5.34 and a 200 day simple moving average of C$5.56. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62.

Insider Buying and Selling

In related news, Director Samira Sakhia bought 20,000 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan acquired 90,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, with a total value of C$463,672.44. 45.62% of the stock is currently owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.